1 / 3

High Affinity YV9 TCRs Enhance Specificity against Reverse Transcriptase Inhibitor Mutations

Discover how YV9 pentamer TCRs recognize drug escape mutations and enhance CD4 effector function. Explore the potential of high-affinity YV9 TCRs in immunotherapy with ART chemotherapeutics.

cassandra-gilbert
Download Presentation

High Affinity YV9 TCRs Enhance Specificity against Reverse Transcriptase Inhibitor Mutations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Enhanced TCR Affinity Imparts Specificity to Reverse Transcriptase Inhibitor Resistance-Associated Mutations YV9 pentamer TCR α TCR β

  2. High affinity YV9 Pol TCRs recognize and respond to drug escape mutations (Efavirenz) IL-2 TNFα (Nevirapine) (Lamivudine)

  3. High Affinity YV9 TCR can endow CD4 with effector function CONCLUSIONS KT.A2.CD64.YV9 • MHC Class I restricted haTCRTransduction of CD4 cells imparts effector-like function • Enhanced affinity increases breadth and sensitivity of epitope recognition to include common drug escape mutations • High affinity YV9 TCRs may be attractive as a potential immunotherapy agent to be used in combination with current ART chemotherapeutics 45.7% transduced 70.8% transduced 77.2% transduced TNFα Acknowledgements: A.Klattenhoff, C. Baiduc, J.L. Riley IL-2

More Related